
Alcon Financial Statements 2025-2006 | ALC
Annual Financial Statements Alcon
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
42.9 B | 45.9 B | 42.6 B | 40.5 B | 42.6 B | 32.1 B | 27.5 B | - | 40.3 B | - | - | - | - | - | - | - | - | - | - | - |
Shares |
493 M | 494 M | 493 M | 491 M | 490 M | 488 M | 488 M | - | 489 M | - | - | - | - | - | - | 301 M | 299 M | 299 M | - | - |
Historical Prices |
87.1 | 92.9 | 86.5 | 82.4 | 86.9 | 65.7 | 56.3 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
980 M | 1.02 B | 974 M | 335 M | 376 M | -531 M | -656 M | -227 M | 256 M | -170 M | - | - | - | - | - | 521 M | 458 M | 2.05 B | 1.59 B | - |
Revenue |
10.4 B | 9.91 B | 9.46 B | 8.72 B | 8.29 B | 6.83 B | 7.51 B | 7.15 B | 6.79 B | 6.6 B | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
4.59 B | 4.33 B | 4.14 B | 3.91 B | 3.58 B | 3.83 B | 3.72 B | 3.96 B | 3.59 B | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
5.74 B | 5.51 B | 5.25 B | 4.75 B | 4.65 B | 2.94 B | 3.66 B | 3.19 B | 3.2 B | 3.13 B | - | - | - | - | - | 5.5 B | 4.88 B | 4.82 B | 4.2 B | - |
Operating Income |
1.36 B | 1.41 B | 1.04 B | 672 M | 580 M | -482 M | -187 M | -248 M | -77 M | - | - | - | - | - | - | 576 M | 537 M | 2.21 B | 1.88 B | - |
Interest Expense |
204 M | 192 M | 189 M | 134 M | 120 M | 124 M | 113 M | 24 M | 27 M | - | - | - | - | - | - | 9 M | 16 M | 51 M | 50 M | - |
EBITDA |
1.36 B | 1.41 B | 1.04 B | 672 M | 580 M | -482 M | -187 M | -248 M | -77 M | 1.29 B | - | - | - | - | - | 788 M | 731 M | 2.38 B | 2.04 B | - |
Operating Expenses |
- | - | - | - | - | 3.37 B | 3.85 B | 3.44 B | 3.28 B | 3.1 B | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
3.45 B | 3.25 B | 272 M | 255 M | 251 M | - | 2.8 B | 2.79 B | 2.6 B | 2.53 B | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Alcon
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q4 | 2009-Q3 | 2009-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | 494 M | - | 493 M | - | 492 M | - | - | - | - | - | - | 493 M | - | - | - | 489 M | - | - | - | 488 M | - | - | - | 488 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -230 K | 299 M | 299 M | 300 M | 299 M | 299 M | 299 M |
Net Income |
- | 223 M | - | 169 M | - | 148 M | - | - | - | - | - | - | 151 M | - | - | - | -422 M | - | - | - | -390 M | - | - | - | 15 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 452 M | 515 M | 582 M | 452 M | -37 M | 627 M | 567 M |
Revenue |
- | 2.5 B | - | 2.42 B | - | 2.22 B | - | - | - | - | - | - | 2.11 B | - | - | - | 1.21 B | - | - | - | 1.9 B | - | - | - | 1.82 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | 1.11 B | - | 1.04 B | - | 999 M | - | - | - | - | - | - | 875 M | - | - | - | 854 M | - | - | - | 922 M | - | - | - | 942 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | 1.37 B | - | 1.36 B | - | 1.2 B | - | - | - | - | - | - | 1.22 B | - | - | - | 345 M | - | - | - | 947 M | - | - | - | 878 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.21 B | 1.22 B | 1.26 B | 1.14 B | 566 M | 1.18 B | 1.32 B |
Operating Income |
- | 318 M | - | 270 M | - | 200 M | - | - | - | - | - | - | 229 M | - | - | - | -466 M | - | - | - | -53 M | - | - | - | 38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 514 M | 578 M | 632 M | 514 M | 243 M | 494 M | 646 M |
Interest Expense |
- | 50 M | - | 48 M | - | 31 M | - | - | - | - | - | - | 30 M | - | - | - | 30 M | - | - | - | 35 M | - | - | - | 6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -146 M | 6 M | 2 M | 4 M | 68 M | -42 M | 1 M |
EBITDA |
- | 318 M | - | 270 M | - | 200 M | - | - | - | - | - | - | 229 M | - | - | - | -466 M | - | - | - | -53 M | - | - | - | 38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 526 M | 583 M | 637 M | 521 M | 272 M | 501 M | 652 M |
General and Administrative Expenses |
- | 837 M | - | 832 M | - | 803 M | - | - | - | - | - | - | 69 M | - | - | - | 62 M | - | - | - | 54 M | - | - | - | 49 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Main types of financial statements Alcon ALCFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Alcon plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
The Cooper Companies
COO
|
$ 76.17 | 0.02 % | $ 15.2 B | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
Glaukos Corporation
GKOS
|
$ 184.53 | 1.51 % | $ 10.6 B | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Haemonetics Corporation
HAE
|
$ 90.8 | 0.46 % | $ 4.28 B | ||
|
Harvard Bioscience
HBIO
|
$ 6.66 | 0.43 % | $ 296 M | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
BioLife Solutions
BLFS
|
$ 35.07 | 0.74 % | $ 1.67 B | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
AtriCure
ATRC
|
$ 44.3 | 1.86 % | $ 2.12 B | ||
|
ICU Medical
ICUI
|
$ 182.98 | 0.22 % | $ 4.51 B | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M | ||
|
AngioDynamics
ANGO
|
$ 15.85 | 1.21 % | $ 658 M | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
Nephros
NEPH
|
$ 4.63 | 0.21 % | $ 49.1 M | ||
|
iRhythm Technologies
IRTC
|
$ 126.44 | 2.66 % | $ 4.05 B | ||
|
Pulse Biosciences
PLSE
|
$ 44.54 | 0.02 % | $ 3 B | ||
|
ResMed
RMD
|
$ 224.46 | 0.22 % | $ 32.7 B | ||
|
InfuSystem Holdings
INFU
|
$ 12.27 | 1.96 % | $ 253 M | ||
|
Repligen Corporation
RGEN
|
$ 166.83 | 0.01 % | $ 9.38 M | ||
|
Baxter International
BAX
|
$ 26.73 | 0.37 % | $ 13.7 B | ||
|
Pro-Dex
PDEX
|
$ 67.02 | 0.17 % | $ 220 B | ||
|
Intuitive Surgical
ISRG
|
$ 394.51 | 0.05 % | $ 141 B | ||
|
STERIS plc
STE
|
$ 233.28 | 0.24 % | $ 22.9 B | ||
|
electroCore
ECOR
|
$ 9.97 | 0.3 % | $ 84.6 K | ||
|
West Pharmaceutical Services
WST
|
$ 349.42 | 0.94 % | $ 25.3 B | ||
|
Merit Medical Systems
MMSI
|
$ 90.76 | 0.29 % | $ 5.37 B | ||
|
Milestone Scientific
MLSS
|
$ 0.5 | 5.33 % | $ 41 M | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.59 | 0.09 % | $ 2.31 B | ||
|
Envista Holdings Corporation
NVST
|
$ 28.07 | 0.04 % | $ 4.72 B | ||
|
Masimo Corporation
MASI
|
- | - | $ 9.59 B | ||
|
Microbot Medical
MBOT
|
$ 1.55 | 0.11 % | $ 71 M | ||
|
STAAR Surgical Company
STAA
|
$ 26.18 | 3.36 % | $ 1.3 B | ||
|
Stereotaxis
STXS
|
$ 1.38 | 2.86 % | $ 126 M | ||
|
Repro Med Systems
KRMD
|
$ 3.4 | 2.26 % | $ 157 M | ||
|
OraSure Technologies
OSUR
|
$ 3.84 | 7.2 % | $ 282 M | ||
|
Teleflex Incorporated
TFX
|
$ 137.17 | 0.1 % | $ 6.12 B | ||
|
LeMaitre Vascular
LMAT
|
$ 82.38 | 0.55 % | $ 1.86 B | ||
|
Becton, Dickinson and Company
BDX
|
$ 183.4 | 0.79 % | $ 52.8 B | ||
|
Retractable Technologies
RVP
|
$ 0.69 | 2.99 % | $ 20.7 M | ||
|
Utah Medical Products
UTMD
|
$ 71.0 | 0.14 % | $ 230 M |